Bruker (NASDAQ: BRKR) reported Q1 EPS of $0.44, $0.12 better than the analyst estimate of $0.32. Revenue for the quarter came in at $554.7 million versus the consensus estimate of $513.06 million.

Frank H. Laukien, President and CEO of Bruker, commented: “Bruker had an excellent start to 2021, with strong year-over-year revenue growth and remarkable operating performance improvements. During the quarter, we experienced strong revenue growth for our Project Accelerate products and solutions, particularly for proteomics and biopharma solutions, as well as for our core scientific instruments from strengthening academic, applied, industrial and semiconductor markets.”

Dr. Laukien continued: “With robust Scientific Instruments order trends in the first quarter, we are raising our full year 2021 revenue growth, operating margin and earnings outlook. We believe Bruker is now well positioned for a strong year, as we invest in our very large Project Accelerate 2.0 opportunities in proteomics, spatial biology and diagnostics, as well as in operational excellence and productivity throughout Bruker.”

GUIDANCE:

Bruker sees FY2021 EPS of $1.82-$1.87, versus the consensus of $1.82.

For earnings history and earnings-related data on Bruker (BRKR) click here.